Effect of M2 muscarinic receptor antagonist 4-DAMP, on prostaglandin synthesis and mechanical function in the isolated rabbit heart

Neelam Jaiswal, Gunter Lambrecht, Ernst Mutschler, Kafait Malik

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

1. 1. Muscarinic agonist acetylcholine (ACh) (non-selective) and arecaidine propargyl ester (APE) (M2 selective agonist) produced a increase in the output of 6-keto PGF and a decrease in the heart rate and myocordial developed tension in a dose-dependent manner. 2. 2. Lower doses of ACh (1.0-5.0 nmol) caused coronary vasodilation, whereas higher doses of ACh (10.0 nmol) and lower as well as higher doses of APE produced a biophasic effect-an initial vasodilation followed by vasoconstriction. 3. 3. The increase in 6-keto PGF output elicited by 3 nmol of ACh or APE was inhibited by 10 nM of classical muscarinic receptor antagonist atropine or by the selective M muscarinic receptor antagonist 4-(diphenylacetoxy-N-methyl piperidine) methiodide (4-DAMP). 4. 4. The decrease in heart rate and myocardial developed tension produced by ACh and APE was attenuated by atropine and 4-DAMP. The coronary vasodilator effect of ACh and APE and the vasoconstrictor effect of APE were also attenuated by both of these muscarinic antagonists.

Original languageEnglish (US)
Pages (from-to)497-502
Number of pages6
JournalGeneral Pharmacology
Volume20
Issue number4
DOIs
StatePublished - Jan 1 1989

Fingerprint

Muscarinic Antagonists
Acetylcholine
Prostaglandins
Rabbits
Atropine
Vasodilation
Heart Rate
Muscarinic Agonists
Vasoconstrictor Agents
Muscarinic Receptors
Vasoconstriction
Vasodilator Agents
arecaidine esters
piperidine

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Effect of M2 muscarinic receptor antagonist 4-DAMP, on prostaglandin synthesis and mechanical function in the isolated rabbit heart. / Jaiswal, Neelam; Lambrecht, Gunter; Mutschler, Ernst; Malik, Kafait.

In: General Pharmacology, Vol. 20, No. 4, 01.01.1989, p. 497-502.

Research output: Contribution to journalArticle

@article{ef7dbb7390ae4cfa93ceca1547f9df9d,
title = "Effect of M2 muscarinic receptor antagonist 4-DAMP, on prostaglandin synthesis and mechanical function in the isolated rabbit heart",
abstract = "1. 1. Muscarinic agonist acetylcholine (ACh) (non-selective) and arecaidine propargyl ester (APE) (M2 selective agonist) produced a increase in the output of 6-keto PGF1α and a decrease in the heart rate and myocordial developed tension in a dose-dependent manner. 2. 2. Lower doses of ACh (1.0-5.0 nmol) caused coronary vasodilation, whereas higher doses of ACh (10.0 nmol) and lower as well as higher doses of APE produced a biophasic effect-an initial vasodilation followed by vasoconstriction. 3. 3. The increase in 6-keto PGF1α output elicited by 3 nmol of ACh or APE was inhibited by 10 nM of classical muscarinic receptor antagonist atropine or by the selective M2β muscarinic receptor antagonist 4-(diphenylacetoxy-N-methyl piperidine) methiodide (4-DAMP). 4. 4. The decrease in heart rate and myocardial developed tension produced by ACh and APE was attenuated by atropine and 4-DAMP. The coronary vasodilator effect of ACh and APE and the vasoconstrictor effect of APE were also attenuated by both of these muscarinic antagonists.",
author = "Neelam Jaiswal and Gunter Lambrecht and Ernst Mutschler and Kafait Malik",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/0306-3623(89)90202-4",
language = "English (US)",
volume = "20",
pages = "497--502",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of M2 muscarinic receptor antagonist 4-DAMP, on prostaglandin synthesis and mechanical function in the isolated rabbit heart

AU - Jaiswal, Neelam

AU - Lambrecht, Gunter

AU - Mutschler, Ernst

AU - Malik, Kafait

PY - 1989/1/1

Y1 - 1989/1/1

N2 - 1. 1. Muscarinic agonist acetylcholine (ACh) (non-selective) and arecaidine propargyl ester (APE) (M2 selective agonist) produced a increase in the output of 6-keto PGF1α and a decrease in the heart rate and myocordial developed tension in a dose-dependent manner. 2. 2. Lower doses of ACh (1.0-5.0 nmol) caused coronary vasodilation, whereas higher doses of ACh (10.0 nmol) and lower as well as higher doses of APE produced a biophasic effect-an initial vasodilation followed by vasoconstriction. 3. 3. The increase in 6-keto PGF1α output elicited by 3 nmol of ACh or APE was inhibited by 10 nM of classical muscarinic receptor antagonist atropine or by the selective M2β muscarinic receptor antagonist 4-(diphenylacetoxy-N-methyl piperidine) methiodide (4-DAMP). 4. 4. The decrease in heart rate and myocardial developed tension produced by ACh and APE was attenuated by atropine and 4-DAMP. The coronary vasodilator effect of ACh and APE and the vasoconstrictor effect of APE were also attenuated by both of these muscarinic antagonists.

AB - 1. 1. Muscarinic agonist acetylcholine (ACh) (non-selective) and arecaidine propargyl ester (APE) (M2 selective agonist) produced a increase in the output of 6-keto PGF1α and a decrease in the heart rate and myocordial developed tension in a dose-dependent manner. 2. 2. Lower doses of ACh (1.0-5.0 nmol) caused coronary vasodilation, whereas higher doses of ACh (10.0 nmol) and lower as well as higher doses of APE produced a biophasic effect-an initial vasodilation followed by vasoconstriction. 3. 3. The increase in 6-keto PGF1α output elicited by 3 nmol of ACh or APE was inhibited by 10 nM of classical muscarinic receptor antagonist atropine or by the selective M2β muscarinic receptor antagonist 4-(diphenylacetoxy-N-methyl piperidine) methiodide (4-DAMP). 4. 4. The decrease in heart rate and myocardial developed tension produced by ACh and APE was attenuated by atropine and 4-DAMP. The coronary vasodilator effect of ACh and APE and the vasoconstrictor effect of APE were also attenuated by both of these muscarinic antagonists.

UR - http://www.scopus.com/inward/record.url?scp=0024475142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024475142&partnerID=8YFLogxK

U2 - 10.1016/0306-3623(89)90202-4

DO - 10.1016/0306-3623(89)90202-4

M3 - Article

VL - 20

SP - 497

EP - 502

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 4

ER -